Literature DB >> 11981158

Effects of analgesics on delayed postherpetic pain in mice.

Ichiro Takasaki1, Atsushi Sasaki, Tsugunobu Andoh, Hiroshi Nojima, Kimiyasu Shiraki, Yasushi Kuraishi.   

Abstract

BACKGROUND: Postherpetic neuralgia is pain that persists long after the disappearance of the cutaneous lesions of herpes zoster. However, the mechanisms of this delayed pain are unclear. Herpes simplex virus infection induces cutaneous lesions and pain-related responses in mice. The authors examined whether such responses would persist after the disappearance of the cutaneous lesions and whether some analgesics would be effective against them.
METHODS: Female BALB/c mice were inoculated with herpes simplex virus type 1 on the unilateral hind paw. Pain-related responses of hind paw were determined using von Frey filaments. Beginning 5 days after inoculation, mice were given perorally the antiherpes agent acyclovir five times a day for 7 days. Effects of morphine (3-5 mg/kg subcutaneously), gabapentin (30-100 mg/kg perorally), mexiletine (10-30 mg/kg intraperitoneally), and diclofenac (30 mg/kg intraperitoneally) on pain-related responses were examined on days 25-35 after inoculation.
RESULTS: Viral inoculation induced cutaneous lesions and pain-related responses beginning on day 5 after inoculation. Acyclovir treatment healed all skin lesions by day 15 after inoculation. Approximately half of the mice given acyclovir showed pain-related responses at least until day 40 after inoculation. Morphine, gabapentin, and mexiletine dose-dependently inhibited pain-related responses, but diclofenac had no effects.
CONCLUSIONS: The authors show a mouse model of delayed postherpetic pain. This may be useful for manifesting the mechanisms of postherpetic neuralgia and the factors contributing to the transition from acute herpetic pain to delayed postherpetic pain. This may also be useful for the development of new analgesics against postherpetic neuralgia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981158     DOI: 10.1097/00000542-200205000-00021

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

1.  Neuroimmune-Glia Interactions in the Sensory Ganglia Account for the Development of Acute Herpetic Neuralgia.

Authors:  Jaqueline R Silva; Alexandre H Lopes; Jhimmy Talbot; Nerry T Cecilio; Mateus F Rossato; Rangel L Silva; Guilherme R Souza; Cassia R Silva; Guilherme Lucas; Benedito A Fonseca; Eurico Arruda; Jose C Alves-Filho; Fernando Q Cunha; Thiago M Cunha
Journal:  J Neurosci       Date:  2017-06-02       Impact factor: 6.167

2.  Herpes simplex virus type-1 latency-associated transcript-induced immunoreactivity of substance P in trigeminal neurons is reversed by bone morphogenetic protein-7.

Authors:  Mohamed A Hamza; Dennis M Higgins; William T Ruyechan
Journal:  Neurosci Lett       Date:  2006-12-15       Impact factor: 3.046

3.  Gabapentin alleviates chronic spontaneous pain and acute hypoxia-related pain in a mouse model of sickle cell disease.

Authors:  Katelyn E Sadler; Sarah N Langer; Anthony D Menzel; Francie Moehring; Ashley N Erb; Amanda M Brandow; Cheryl L Stucky
Journal:  Br J Haematol       Date:  2019-06-27       Impact factor: 6.998

4.  Latent herpes simplex virus infection of sensory neurons alters neuronal gene expression.

Authors:  Martha F Kramer; W James Cook; Frederick P Roth; Jia Zhu; Holly Holman; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 5.  Gabapentin: in postherpetic neuralgia.

Authors:  Monique P Curran; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

6.  Involvement of Tyr1472 phosphorylation of NMDA receptor NR2B subunit in postherpetic neuralgia in model mice.

Authors:  Sawako Unezaki; Atsushi Sasaki; Tamaki Mabuchi; Shinji Matsumura; Tayo Katano; Takanobu Nakazawa; Naoko Nishio; Tsugunobu Andoh; Tadashi Yamamoto; Terumasa Nakatsuka; Yasushi Kuraishi; Seiji Ito
Journal:  Mol Pain       Date:  2012-08-21       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.